Drug Trial Radar · NCT06327295
A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Jun 30, 2025
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- AmtixBio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis
Conditions
- Onychomycosis
Interventions
ATB1651-102- Cohort 1Drug
Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
ATB1651-102- Cohort 2Drug
Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
ATB1651-102- Cohort 3Drug
Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
ATB1651-102- Cohort 4Drug
Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
PlaceboDrug
participants will receive matching placebo across cohorts 1-4 of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the complete cure rate with topical ATB1651 3% and ATB1651 5% in participants with mild to moderate onychomycosis.Time frame: From screening to end of study treatment up to 252 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research Christchurch
Christchurch, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.